Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-1088 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 400 mg CC-1088 | EXPERIMENTAL | - |
| 800 mg CC-1088 | EXPERIMENTAL | - |
| 1200 mg CC-1088 | EXPERIMENTAL | - |
| 1500 mg CC-1088 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CC-1088 | DRUG | 400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily) |
Inclusion Criteria: * Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not therapy related. * Age ≥ 18 at the time of signing informed consent * Patient must be able to adhere to the study visit schedule and other protocol requirements. * Patient must understand and volun...
Top 20 of 34 competitors
CC-1088 is an investigational small molecule being studied for the treatment of Myelodysplastic Syndrome, a group of bone marrow disorders. It is currently in Phase 2 clinical development and is not yet approved by the FDA. The drug is being evaluated for its safety and preliminary efficacy in patients with this condition.
CC-1088 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's potential in treating Myelodysplastic Syndrome.
CC-1088 is in Phase 2 clinical development for Myelodysplastic Syndrome. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains under investigation for this indication.
CC-1088 has one completed Phase 2 clinical trial registered under NCT00045786, titled 'Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes.' The trial enrolled 18 participants in the United States and included patients aged 18 years and older.
CC-1088 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for Myelodysplastic Syndrome. The completed Phase 2 trial assessed safety and preliminary efficacy, but the drug has not received regulatory approval for any use.